A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )

Trial Profile

A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Saroglitazar (Primary)
  • Indications Cholangitis; Primary biliary cirrhosis
  • Focus Therapeutic Use
  • Acronyms EPICS
  • Sponsors Zydus Cadila
  • Most Recent Events

    • 27 Jun 2017 Planned initiation date changed from 1 Apr 2017 to 1 Jul 2017.
    • 18 Apr 2017 New trial record
    • 12 Apr 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top